Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.

Date publication

mai 2021

Journal

Clinical research in cardiology : official journal of the German Cardiac Society

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Coiro S, Girerd N, McMurray JJV, Pitt B, Swedberg K, van Veldhuisen DJ, Lamiral Z, Rossignol P, Zannad F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33956209

Résumé

Loop diuretics are the mainstay of congestion treatment in patients with heart failure (HF). We assessed the association between baseline loop diuretic use and outcome. We also compared the increment in risk related to diuretic dose with conventional prognostic enrichment criteria used in the EMPHASIS-HF trial, which included patients with systolic HF and mild symptoms, such as prior hospitalization and elevated natriuretic peptides.

Mots clés

Eplerenone, Heart failure hospitalization, Heart failure with reduced ejection faction, Loop diuretics, Prognostic enrichment criteria

Référence

Clin Res Cardiol. 2021 May 6;: